1-3 of 3
Laura M. Bruzek
Close
Sort by
Journal Articles

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Clinical Trials & Observations
Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett-Mayer, Peter L. Greenberg, John J. Wright, Judith E. Karp
Journal: Blood
Blood (2006) 109 (4): 1387–1394.
https://doi.org/10.1182/blood-2006-04-014357
Published: 2006
Journal Articles

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

Clinical Trials & Observations
Melissa Alsina, Rafael Fonseca, Edward F. Wilson, A. Nelida Belle, Elvira Gerbino, Tammy Price-Troska, Rose M. Overton, Gregory Ahmann, Laura M. Bruzek, Alex A. Adjei, Scott H. Kaufmann, John J. Wright, Daniel Sullivan, Benjamin Djulbegovic, Alan B. Cantor, Philip R. Greipp, William S. Dalton, Saïd M. Sebti
Journal: Blood
Blood (2004) 103 (9): 3271–3277.
https://doi.org/10.1182/blood-2003-08-2764
Published: 2004
Journal Articles

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

Joya Chandra, Jennifer Hackbarth, Son Le, David Loegering, Nancy Bone, Laura M. Bruzek, Ven L. Narayanan, Alex A. Adjei, Neil E. Kay, Ayalew Tefferi, Judith E. Karp, Edward A. Sausville, Scott H. Kaufmann
Journal: Blood
Blood (2003) 102 (13): 4512–4519.
https://doi.org/10.1182/blood-2003-02-0562
Published: 2003